HMGN2 and neoplasm: In general, it seemed that the subnetworks of the non-metastatic patients contained more genes that have been linked to better prognostic outcomes such as JUP, PCBP1, and HMGN2 in GSM615695 [50–52] or RASA1, IL6ST, KRT19, and RPS14 in GSM150990 [53–56], while the networks of both metastatic patients harbored genes that are known to be involved in aggressive tumor growth or therapy resistance which might explain the early metastatic spread in these patients.